DK2503338T3 - CD73 as a biomarker to monitor the development of disease and evaluate the effectiveness of treatments - Google Patents
CD73 as a biomarker to monitor the development of disease and evaluate the effectiveness of treatments Download PDFInfo
- Publication number
- DK2503338T3 DK2503338T3 DK12002502T DK12002502T DK2503338T3 DK 2503338 T3 DK2503338 T3 DK 2503338T3 DK 12002502 T DK12002502 T DK 12002502T DK 12002502 T DK12002502 T DK 12002502T DK 2503338 T3 DK2503338 T3 DK 2503338T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- activity
- treatment
- mice
- biomarker
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 20
- 201000010099 disease Diseases 0.000 title claims description 19
- 239000000090 biomarker Substances 0.000 title claims description 10
- 102100022464 5'-nucleotidase Human genes 0.000 title claims 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 title claims 3
- 238000011161 development Methods 0.000 title description 4
- 239000012530 fluid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 206010063837 Reperfusion injury Diseases 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 5
- 230000000451 tissue damage Effects 0.000 claims description 4
- 231100000827 tissue damage Toxicity 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 22
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 229960005305 adenosine Drugs 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 108090000467 Interferon-beta Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 206010033645 Pancreatitis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 102000004008 5'-Nucleotidase Human genes 0.000 description 3
- 206010027654 Allergic conditions Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 229960001388 interferon-beta Drugs 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 101150078577 Adora2b gene Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010061660 Artery dissection Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 229940127272 CD73 inhibitor Drugs 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 101150036449 SIRPA gene Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- OLCWZBFDIYXLAA-IOSLPCCCSA-N adenosine 5'-methylenediphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O OLCWZBFDIYXLAA-IOSLPCCCSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006453 vascular barrier function Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20070795A FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| EP08842581A EP2201376B1 (en) | 2007-10-24 | 2008-10-15 | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2503338T3 true DK2503338T3 (en) | 2015-03-09 |
Family
ID=38656804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08842581.4T DK2201376T3 (da) | 2007-10-24 | 2008-10-15 | En ny biomarkør til overvågning af udviklingen af sygdomme og vurdering af effektiviteten af terapier |
| DK12002502T DK2503338T3 (en) | 2007-10-24 | 2008-10-15 | CD73 as a biomarker to monitor the development of disease and evaluate the effectiveness of treatments |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08842581.4T DK2201376T3 (da) | 2007-10-24 | 2008-10-15 | En ny biomarkør til overvågning af udviklingen af sygdomme og vurdering af effektiviteten af terapier |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100209942A1 (enExample) |
| EP (2) | EP2201376B1 (enExample) |
| JP (2) | JP4982610B2 (enExample) |
| KR (2) | KR20100059902A (enExample) |
| CA (1) | CA2702635A1 (enExample) |
| CY (2) | CY1113403T1 (enExample) |
| DK (2) | DK2201376T3 (enExample) |
| ES (2) | ES2389751T3 (enExample) |
| FI (1) | FI20070795A0 (enExample) |
| HR (2) | HRP20120743T1 (enExample) |
| PL (2) | PL2201376T3 (enExample) |
| PT (2) | PT2201376E (enExample) |
| SI (2) | SI2503338T1 (enExample) |
| WO (1) | WO2009053523A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2712303C (en) | 2008-01-18 | 2015-03-31 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| BR112013001754A2 (pt) | 2010-07-23 | 2016-05-31 | Harvard College | método para detectar marcas de doença ou condições em fluídos corpóreos |
| EP2596134B1 (en) | 2010-07-23 | 2020-04-08 | President and Fellows of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| WO2012012694A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
| US20130210647A1 (en) | 2010-07-23 | 2013-08-15 | President And Fellows Of Harvard College | Methods of Detecting Cardiovascular Diseases or Conditions |
| BR112014031365A2 (pt) | 2012-06-15 | 2017-06-27 | Stylli Harry | métodos de detectar doenças ou condições |
| SG11201408383SA (en) | 2012-06-15 | 2015-01-29 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
| BR112015018213B1 (pt) | 2013-02-14 | 2022-12-20 | Faron Pharmaceuticals Oy | Métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico |
| EP4513187A3 (en) | 2013-03-09 | 2025-05-21 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| WO2014164366A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting cancer |
| EP4075139B1 (en) | 2014-09-11 | 2024-05-22 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| EP3789399A1 (en) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| LT3221363T (lt) | 2014-11-21 | 2020-08-10 | Bristol-Myers Squibb Company | Antikūnai prieš cd73 ir jų panaudojimas |
| GB201706747D0 (en) | 2017-04-27 | 2017-06-14 | Queen Mary | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736343A (en) * | 1995-08-18 | 1998-04-07 | Landry; Donald | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| EP0862652A1 (en) * | 1995-10-13 | 1998-09-09 | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
| HUP0002003A3 (en) * | 2000-05-24 | 2003-01-28 | Pronuk Biotechnologia Kft | Process and reagent-kit for determining of 5'-nucleotidase activity |
| WO2002077174A2 (en) * | 2001-03-27 | 2002-10-03 | Zymogenetics, Inc. | Human cytokine receptor |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| DE602004027797D1 (de) * | 2003-03-28 | 2010-08-05 | Faron Pharmaceuticals Oy | Erhöhung des adenosin-spiegels durch cytokin-induzierte expression von cd73 |
| FI20030467A0 (fi) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Menetelmä tulehdustilojen hoitamiseen |
| WO2005000860A2 (en) * | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
| EP1917528B1 (en) * | 2005-08-24 | 2011-08-17 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| FI20051003A0 (fi) | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| EP2021350B1 (en) * | 2006-03-21 | 2016-12-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Phosphorylated a2a receptor agonists |
| AU2007273055B2 (en) * | 2006-07-14 | 2014-05-01 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
-
2007
- 2007-10-24 FI FI20070795A patent/FI20070795A0/fi not_active Application Discontinuation
-
2008
- 2008-10-15 HR HRP20120743AT patent/HRP20120743T1/hr unknown
- 2008-10-15 PL PL08842581T patent/PL2201376T3/pl unknown
- 2008-10-15 KR KR1020107006430A patent/KR20100059902A/ko not_active Ceased
- 2008-10-15 PT PT08842581T patent/PT2201376E/pt unknown
- 2008-10-15 ES ES08842581T patent/ES2389751T3/es active Active
- 2008-10-15 EP EP08842581A patent/EP2201376B1/en active Active
- 2008-10-15 US US12/679,785 patent/US20100209942A1/en not_active Abandoned
- 2008-10-15 SI SI200831377T patent/SI2503338T1/sl unknown
- 2008-10-15 ES ES12002502.8T patent/ES2532361T3/es active Active
- 2008-10-15 PT PT12002502T patent/PT2503338E/pt unknown
- 2008-10-15 WO PCT/FI2008/050576 patent/WO2009053523A1/en not_active Ceased
- 2008-10-15 CA CA2702635A patent/CA2702635A1/en not_active Abandoned
- 2008-10-15 DK DK08842581.4T patent/DK2201376T3/da active
- 2008-10-15 KR KR1020167005473A patent/KR20160029869A/ko not_active Ceased
- 2008-10-15 DK DK12002502T patent/DK2503338T3/en active
- 2008-10-15 PL PL12002502T patent/PL2503338T3/pl unknown
- 2008-10-15 EP EP12002502.8A patent/EP2503338B1/en active Active
- 2008-10-15 SI SI200830723T patent/SI2201376T1/sl unknown
- 2008-10-15 JP JP2010530497A patent/JP4982610B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-23 JP JP2012098081A patent/JP5619810B2/ja not_active Expired - Fee Related
- 2012-10-04 CY CY20121100924T patent/CY1113403T1/el unknown
-
2015
- 2015-02-16 HR HRP20150181TT patent/HRP20150181T1/hr unknown
- 2015-03-06 CY CY20151100234T patent/CY1116089T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2201376T3 (da) | 2012-10-15 |
| EP2201376B1 (en) | 2012-08-08 |
| PL2201376T3 (pl) | 2013-01-31 |
| EP2201376A4 (en) | 2011-03-23 |
| CY1113403T1 (el) | 2016-06-22 |
| FI20070795A0 (fi) | 2007-10-24 |
| KR20100059902A (ko) | 2010-06-04 |
| EP2503338B1 (en) | 2014-12-24 |
| PT2503338E (pt) | 2015-03-05 |
| HRP20120743T1 (hr) | 2012-10-31 |
| PL2503338T3 (pl) | 2015-06-30 |
| ES2532361T3 (es) | 2015-03-26 |
| EP2201376A1 (en) | 2010-06-30 |
| CY1116089T1 (el) | 2017-02-08 |
| CA2702635A1 (en) | 2009-04-30 |
| KR20160029869A (ko) | 2016-03-15 |
| ES2389751T3 (es) | 2012-10-31 |
| SI2201376T1 (sl) | 2012-09-28 |
| EP2503338A2 (en) | 2012-09-26 |
| PT2201376E (pt) | 2012-08-20 |
| JP2012159514A (ja) | 2012-08-23 |
| EP2503338A3 (en) | 2013-03-13 |
| JP2011501176A (ja) | 2011-01-06 |
| SI2503338T1 (sl) | 2015-06-30 |
| JP5619810B2 (ja) | 2014-11-05 |
| JP4982610B2 (ja) | 2012-07-25 |
| US20100209942A1 (en) | 2010-08-19 |
| HRP20150181T1 (hr) | 2015-06-19 |
| WO2009053523A1 (en) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2503338T3 (en) | CD73 as a biomarker to monitor the development of disease and evaluate the effectiveness of treatments | |
| Chaiworapongsa et al. | Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award | |
| CA2744434C (en) | Methods, devices and kits for detecting or monitoring acute kidney injury | |
| Wang et al. | Correlation between plasma, synovial fluid and articular cartilage Interleukin-18 with radiographic severity in 33 patients with osteoarthritis of the knee | |
| Gorska et al. | Comparative study of IL-33 and IL-6 levels in different respiratory samples in mild-to-moderate asthma and COPD | |
| US8975081B2 (en) | Biomarker for monitoring development of diseases and assessing the efficacy of therapies | |
| JP2025019061A (ja) | 術後有害事象の診断または予後 | |
| Klein et al. | Response of routine inflammatory biomarkers and novel Pancreatic Stone Protein to inhalation injury and its interference with sepsis detection in severely burned patients | |
| JP5296701B2 (ja) | 線維性疾患および線維増殖性疾患を処置および診断するための方法 | |
| US20130309695A1 (en) | Methods of diagnosing asthma | |
| Oraby et al. | Adiponectin as inflammatory biomarker of chronic obstructive pulmonary disease | |
| US7709215B2 (en) | Method for diagnosing and treating acute joint injury | |
| Marchesi et al. | Acute inflammatory state during influenza infection and endothelial function | |
| Saini et al. | Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation | |
| Jin et al. | A halotyrosine antibody that detects increased protein modifications in asthma patients | |
| Rubinsztajn et al. | Metabolic syndrome as a factor affecting systemic inflammation in patients with chronic obstructive pulmonary disease | |
| Szalardy et al. | Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis | |
| CN117529664A (zh) | 用于预测脓毒症和脓毒性休克的方法 | |
| JP6062439B2 (ja) | 早期腎障害の評価マーカーとその測定方法 | |
| Kayani et al. | Aortoenteric fistula as shown by multidetector computed tomography | |
| Sumi et al. | Regions of Inflammation in mouse asthma correspond to regions of heme-free soluble guanylyl cyclase and can be tracked by marked expression of heme-oxygenase-1 | |
| US20090048121A1 (en) | Screening Method for the Early Diagnosis of Cerebral Vasospasm | |
| Erol et al. | Polikistik over sendromlu kadınlarda SCUBE1 düzeyi | |
| Gheorghiu et al. | FRI0428 Mean number of capillaries is associated with disease activity at 6 months follow-up in systemic sclerosis patients | |
| HK40016117A (en) | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |